clinical trial · NCT07859085
A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma
Genentech, Inc.·phase1·not yet recruiting·n = 388
Colorectal NeoplasmsPancreatic Ductal AdenocarcinomaGDC-7035PanitumumabmFOLFOX6FOLFIRImFOLFIRINOXGem-nabP
brief summary
The primary purpose of this study is to evaluate the safety of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with KRAS G12D-mutated metastatic colorectal cancer (CRC) or pancreatic ductal adenocarcinoma (PDAC). The study consists of a safety run-in period followed by a randomized/expansion period.
started
Nov 30, 2026
primary completion
Mar 30, 2029
completion
Mar 30, 2029
last updated
Nov 10, 2026
official title
A Phase Ib, Multicenter, Randomized Study Evaluating the Safety and Activity of GDC-7035 With Anti-Cancer Therapies as First-Line Treatment in Patients With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol